FHD-609

· Foghorn Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FHD-609, covering 2025-03-04 to 2025-03-04. Get the full timeline:

Most recent: Clinical Trial Update: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors [Phase 1]